Making a case for del(1p) as a high-risk abnormality in multiple myeloma

被引：1
|
作者：
Schmidt, Timothy M. M. [1 ,2 ]
机构：
[1] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[2] 600 Highland Ave,K6-544 MC 5669 Clin Sci Ctr, Madison, WI 53792 USA
来源：
CANCER | 2023年 / 129卷 / 16期
关键词：
PROGNOSTIC-FACTOR; DELETIONS; THERAPY; CDKN2C; GENES; 1P;
D O I：
10.1002/cncr.34893
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2450 / 2452
页数：3
相关论文
共 50 条
  • [11] Defining and treating high-risk multiple myeloma
    Usmani, S. Z.
    Rodriguez-Otero, P.
    Bhutani, M.
    Mateos, M-V
    Miguel, J. S.
    LEUKEMIA, 2015, 29 (11) : 2119 - 2125
  • [12] Strategies to Overcome High-Risk Multiple Myeloma
    Sanchez, Larysa
    CANCER JOURNAL, 2021, 27 (03): : 201 - 204
  • [13] Current Review on High-Risk Multiple Myeloma
    Henry S. H. Chan
    Christine I. Chen
    Donna E. Reece
    Current Hematologic Malignancy Reports, 2017, 12 : 96 - 108
  • [14] A High-Risk Survival Classifier for Multiple Myeloma
    Kuiper, Rowan
    Broyl, Annemiek
    de Knegt, Yvonne
    van Vliet, Martin H.
    van Beers, Erik H.
    van der Holt, Bronno
    el Jarari, Laila
    Mulligan, George
    Morgan, Gareth
    Gregory, Walter M.
    Goldschmidt, Hartmut
    Lokhorst, Henk M.
    van Duin, Mark
    Sonneveld, Pieter
    BLOOD, 2011, 118 (21) : 786 - 786
  • [15] Multiple myeloma: high-risk immunophenotypes identified
    Nature Clinical Practice Oncology, 2008, 5 (9): : 496 - 496
  • [16] A HIGH-RISK SURVIVAL SIGNATURE FOR MULTIPLE MYELOMA
    Kuiper, R.
    Broyl, A.
    de Knegt, Y.
    van Vliet, M.
    van Beers, E.
    van der Holt, B.
    el Jarari, L.
    Mulligan, G.
    Gregory, W.
    Morgan, G.
    Goldschmidt, H.
    Lokhorst, H.
    van Duin, M.
    Sonneveld, P.
    HAEMATOLOGICA, 2012, 97 : 223 - 223
  • [17] High-risk Multiple Myeloma: Definition and Management
    Joseph, Nisha S.
    Gentili, Silvia
    Kaufman, Jonathan L.
    Lonial, Sagar
    Nooka, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S80 - S87
  • [18] Defining and treating high-risk multiple myeloma
    S Z Usmani
    P Rodriguez-Otero
    M Bhutani
    M-V Mateos
    J S Miguel
    Leukemia, 2015, 29 : 2119 - 2125
  • [19] FOXM1 is a therapeutic target for high-risk multiple myeloma
    C Gu
    Y Yang
    R Sompallae
    H Xu
    V S Tompkins
    C Holman
    D Hose
    H Goldschmidt
    G Tricot
    F Zhan
    S Janz
    Leukemia, 2016, 30 : 873 - 882
  • [20] FOXM1 is a therapeutic target for high-risk multiple myeloma
    Gu, C.
    Yang, Y.
    Sompallae, R.
    Xu, H.
    Tompkins, V. S.
    Holman, C.
    Hose, D.
    Goldschmidt, H.
    Tricot, G.
    Zhan, F.
    Janz, S.
    LEUKEMIA, 2016, 30 (04) : 873 - 882
12345